The results of glucose lowering drugs and glycemic control in inpatients with Diabetes Mellitus in Central Hospital of MNUMS

Abstract

Background: We have recently started using novel glucose lowering drugs and insulin therapies in Mongolia. Mongolian guidelines on diabetes mellitus has been updated in 2021. However there is no study on the use of glucose lowering drugs and insulin in patients with diabetes and their glycemic control. Aim: To study glucose lowering drugs and insulin usage in patients with diabetes and their glycemic control. Materials and Methods: We performed a cross-sectional study and analyzed data was conducted on patients with diabetes mellitus who admitted to central hospital of MNUMS. Results: A total of 262 patients’ data was reviewed. The male patients were 56.9% (n=149) and mean age was 56.4±12.08 years, mean duration of diabetes was 8.6 years (0-34) and 94.0% (n=246) of them had type 2 diabetes. Among all patients, 79% were given glucose lowering drugs and others (21%) were being treated with insulin. Regradring to types of oral glycemic drugs, 47.3 (n=124) was metformin, 14.1 (n=37) was sulfanylurea, and 25.6 (n=67) was incretin based drugs. It was observed that the use of analogue insulin was low: 23.6% of all patients were being treated with insulins. In the study, 30% of all patients did not get tested HbA1c for the last year. Moreover, 60% of patients who had tested HbA1c have poor glycaemic control. Conclusion: Altough nowel drugs and insulin types have been using in Mongolia in recent years for the treatment of diabetes mellitus, approximatily 60% of people with DM have poor glycemic control. Therefore, we need to increase the practical use of guidelines and to improve the management and follow-up in patients with diabetes.